Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 6/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | PI4KA | P42356 | 2/20 | 0.71 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.71 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.71 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.71 |
| ▸ | ADA | P00813 | 4/20 | 0.56 |
| ▸ | PDE2A | O00408 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572183 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL233401 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21539425 | 0.88 | ADORA2A (0.78) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL24860314 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11251758 | 0.86 | ADORA2A (0.75) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL22381495 | 0.85 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21118434 | 0.84 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL754007 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21078554 | 0.83 | ADA (0.73) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL19662193 | 0.83 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11739325-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-29 | — | — | US | disclosed |
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210032620-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-02-04 | — | — | US | disclosed |
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-01-21 | — | — | US | disclosed |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | AJ SCIENCES (YIXING) CO., LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | ADORA2A 17/4885ADORA1 34/4885ADORA2B 31/4885 |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | ADORA2A 1048/4885ADORA1 2085/4885ADORA2B 1814/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | ADORA2A 1787/4885ADORA1 2434/4885ADORA2B 2523/4885 |
| US-20210015915-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | ADORA2A 696/4885ADORA1 780/4885ADORA2B 1077/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | ADORA2A 1048/4885ADORA1 2085/4885ADORA2B 1814/4885 |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | STING1, IRF3, CGAS | ADORA2A 216/4885ADORA1 884/4885ADORA2B 859/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | ADORA2A 216/4885ADORA1 884/4885ADORA2B 859/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | ADORA2A 1252/4885ADORA1 1782/4885ADORA2B 1523/4885 |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R1, PIK3R4 | ADORA2A 3136/4885ADORA1 1794/4885ADORA2B 2418/4885 |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | STING1, IRF3, CGAS | ADORA2A 21/4885ADORA1 30/4885ADORA2B 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.